[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592611":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":461,"collaborators":29,"id":463,"slug":29,"hasResults":464,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":464,"sex":470,"minAge":471,"maxAge":29,"enrollmentInfo":472,"targetDuration":29,"studyType":475,"phases":476,"briefSummary":478,"conditions":479,"keywords":486,"overallStatus":51,"whyStopped":29,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":501},{"fullName":5,"class":6},"Tyra Biosciences, Inc","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Cohort A (DCA)","EXPERIMENTAL","TYRA-300 monotherapy in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",[13],"Drug: TYRA-300 60mg",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose Cohort B (DCB)",[17],"Drug: TYRA-300 50mg",{"label":19,"type":10,"description":20,"interventionNames":21},"Possible Dose Cohort C (DCC)","To Be Determined- TYRA-300 monotherapy in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",[22],"Drug: TYRA-300 Dose TBD",[24,30,34],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","TYRA-300 60mg","Self-administered 60mg dose Oral tablet(s) given daily",[9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"TYRA-300 50mg","Self-administered 50mg dose Oral tablet(s) given daily",[15],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"TYRA-300 Dose TBD","To Be Determined Dose: Self-administered Oral tablet(s) given daily",[19],[39],{"name":40,"affiliation":5,"role":41},"Doug Warner, MD","STUDY_CHAIR",[43],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},"Grace Indyk","CONTACT","858-356-2323","TyraClinicalTrials@tyra.bio",[49,62,72,82,91,100,110,119,129,138,148,158,168,178,187,196,202,211,220,230,239,249,258,268,277,287,296,305,315,324,334,343,352,361,372,381,390,399,408,418,428,434,440,446,452],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":29},"Urology Centers of Alabama","RECRUITING","Homewood","Alabama","35209","United States",{"type":57,"coordinates":58},"Point",[59,60],-86.80082,33.47177,{"lat":60,"lon":59},{"facility":63,"status":51,"city":64,"state":65,"zip":66,"country":55,"cosmosGeoPoint":67,"geoPoint":71,"contacts":29},"Arkansas Urology","Little Rock","Arkansas","72211",{"type":57,"coordinates":68},[69,70],-92.28959,34.74648,{"lat":70,"lon":69},{"facility":73,"status":51,"city":74,"state":75,"zip":76,"country":55,"cosmosGeoPoint":77,"geoPoint":81,"contacts":29},"Tri Valley Urology - Murrieta","Murrieta","California","92562",{"type":57,"coordinates":78},[79,80],-117.21392,33.55391,{"lat":80,"lon":79},{"facility":83,"status":51,"city":84,"state":75,"zip":85,"country":55,"cosmosGeoPoint":86,"geoPoint":90,"contacts":29},"Eisenhower Medical Associates","Rancho Mirage","92270",{"type":57,"coordinates":87},[88,89],-116.41279,33.73974,{"lat":89,"lon":88},{"facility":92,"status":51,"city":93,"state":75,"zip":94,"country":55,"cosmosGeoPoint":95,"geoPoint":99,"contacts":29},"Om Research LLC","San Diego","92123",{"type":57,"coordinates":96},[97,98],-117.16472,32.71571,{"lat":98,"lon":97},{"facility":101,"status":51,"city":102,"state":103,"zip":104,"country":55,"cosmosGeoPoint":105,"geoPoint":109,"contacts":29},"Associated Urological Specialists","Chicago Ridge","Illinois","60415",{"type":57,"coordinates":106},[107,108],-87.77922,41.70142,{"lat":108,"lon":107},{"facility":111,"status":51,"city":112,"state":103,"zip":113,"country":55,"cosmosGeoPoint":114,"geoPoint":118,"contacts":29},"Duly Health and Care","Lisle","60532",{"type":57,"coordinates":115},[116,117],-88.07479,41.80114,{"lat":117,"lon":116},{"facility":120,"status":51,"city":121,"state":122,"zip":123,"country":55,"cosmosGeoPoint":124,"geoPoint":128,"contacts":29},"Urology of Indiana","Greenwood","Indiana","46143",{"type":57,"coordinates":125},[126,127],-86.10665,39.61366,{"lat":127,"lon":126},{"facility":130,"status":51,"city":131,"state":122,"zip":132,"country":55,"cosmosGeoPoint":133,"geoPoint":137,"contacts":29},"First Urology","Jeffersonville","47130",{"type":57,"coordinates":134},[135,136],-85.73718,38.27757,{"lat":136,"lon":135},{"facility":139,"status":51,"city":140,"state":141,"zip":142,"country":55,"cosmosGeoPoint":143,"geoPoint":147,"contacts":29},"University of Kansas Medical Center (KUMC)","Kansas City","Kansas","66160",{"type":57,"coordinates":144},[145,146],-94.62746,39.11417,{"lat":146,"lon":145},{"facility":149,"status":51,"city":150,"state":151,"zip":152,"country":55,"cosmosGeoPoint":153,"geoPoint":157,"contacts":29},"Johns Hopkins University","Baltimore","Maryland","21205",{"type":57,"coordinates":154},[155,156],-76.61219,39.29038,{"lat":156,"lon":155},{"facility":159,"status":51,"city":160,"state":161,"zip":162,"country":55,"cosmosGeoPoint":163,"geoPoint":167,"contacts":29},"Greater Boston Urology","Plymouth","Massachusetts","02360",{"type":57,"coordinates":164},[165,166],-70.66726,41.95844,{"lat":166,"lon":165},{"facility":169,"status":51,"city":170,"state":171,"zip":172,"country":55,"cosmosGeoPoint":173,"geoPoint":177,"contacts":29},"Atlantic Health System","Morristown","New Jersey","07960",{"type":57,"coordinates":174},[175,176],-74.48154,40.79677,{"lat":176,"lon":175},{"facility":179,"status":51,"city":180,"state":171,"zip":181,"country":55,"cosmosGeoPoint":182,"geoPoint":186,"contacts":29},"New Jersey Urology, LLC (Summit Health - Washington Township)","Voorhees Township","08043",{"type":57,"coordinates":183},[184,185],-74.49062,40.4795,{"lat":185,"lon":184},{"facility":188,"status":51,"city":189,"state":189,"zip":190,"country":55,"cosmosGeoPoint":191,"geoPoint":195,"contacts":29},"NYU Langone Health","New York","10016",{"type":57,"coordinates":192},[193,194],-74.00597,40.71427,{"lat":194,"lon":193},{"facility":197,"status":51,"city":189,"state":189,"zip":198,"country":55,"cosmosGeoPoint":199,"geoPoint":201,"contacts":29},"Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers","10065",{"type":57,"coordinates":200},[193,194],{"lat":194,"lon":193},{"facility":203,"status":51,"city":204,"state":189,"zip":205,"country":55,"cosmosGeoPoint":206,"geoPoint":210,"contacts":29},"Associated Medical Professionals of NY","Syracuse","13210",{"type":57,"coordinates":207},[208,209],-76.14742,43.04812,{"lat":209,"lon":208},{"facility":212,"status":51,"city":213,"state":189,"zip":214,"country":55,"cosmosGeoPoint":215,"geoPoint":219,"contacts":29},"The Bronx Veterans Medical Research Foundation, Inc.","The Bronx","10468",{"type":57,"coordinates":216},[217,218],-73.86641,40.84985,{"lat":218,"lon":217},{"facility":221,"status":51,"city":222,"state":223,"zip":224,"country":55,"cosmosGeoPoint":225,"geoPoint":229,"contacts":29},"Duke Cancer Institute","Durham","North Carolina","27705",{"type":57,"coordinates":226},[227,228],-78.89862,35.99403,{"lat":228,"lon":227},{"facility":231,"status":51,"city":232,"state":223,"zip":233,"country":55,"cosmosGeoPoint":234,"geoPoint":238,"contacts":29},"Associate Urologist of North Carolina","Raleigh","27612",{"type":57,"coordinates":235},[236,237],-78.63861,35.7721,{"lat":237,"lon":236},{"facility":240,"status":51,"city":241,"state":242,"zip":243,"country":55,"cosmosGeoPoint":244,"geoPoint":248,"contacts":29},"The James at Brain and Spine Hospital (OSU)","Columbus","Ohio","43210",{"type":57,"coordinates":245},[246,247],-82.99879,39.96118,{"lat":247,"lon":246},{"facility":250,"status":51,"city":251,"state":242,"zip":252,"country":55,"cosmosGeoPoint":253,"geoPoint":257,"contacts":29},"Oregon Urology Institute","Springfield","97477",{"type":57,"coordinates":254},[255,256],-83.80882,39.92423,{"lat":256,"lon":255},{"facility":259,"status":51,"city":260,"state":261,"zip":262,"country":55,"cosmosGeoPoint":263,"geoPoint":267,"contacts":29},"MidLantic Urology","Bala-Cynwyd","Pennsylvania","19004",{"type":57,"coordinates":264},[265,266],-75.23407,40.00761,{"lat":266,"lon":265},{"facility":269,"status":51,"city":270,"state":261,"zip":271,"country":55,"cosmosGeoPoint":272,"geoPoint":276,"contacts":29},"Keystone Urology Specialists","Lancaster","17604",{"type":57,"coordinates":273},[274,275],-76.30551,40.03788,{"lat":275,"lon":274},{"facility":278,"status":51,"city":279,"state":280,"zip":281,"country":55,"cosmosGeoPoint":282,"geoPoint":286,"contacts":29},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":57,"coordinates":283},[284,285],-79.93275,32.77632,{"lat":285,"lon":284},{"facility":288,"status":51,"city":289,"state":280,"zip":290,"country":55,"cosmosGeoPoint":291,"geoPoint":295,"contacts":29},"Carolina Urologic Research Center","Myrtle Beach","29572",{"type":57,"coordinates":292},[293,294],-78.88669,33.68906,{"lat":294,"lon":293},{"facility":297,"status":51,"city":298,"state":280,"zip":299,"country":55,"cosmosGeoPoint":300,"geoPoint":304,"contacts":29},"Lowcounty Urology Clinics, P.A.","North Charleston","29406",{"type":57,"coordinates":301},[302,303],-79.97481,32.85462,{"lat":303,"lon":302},{"facility":306,"status":51,"city":307,"state":308,"zip":309,"country":55,"cosmosGeoPoint":310,"geoPoint":314,"contacts":29},"Conrad Pearson-Memphis","Germantown","Tennessee","38138",{"type":57,"coordinates":311},[312,313],-89.81009,35.08676,{"lat":313,"lon":312},{"facility":316,"status":51,"city":317,"state":308,"zip":318,"country":55,"cosmosGeoPoint":319,"geoPoint":323,"contacts":29},"Urology Associates PC","Nashville","37209",{"type":57,"coordinates":320},[321,322],-86.78444,36.16589,{"lat":322,"lon":321},{"facility":325,"status":51,"city":326,"state":327,"zip":328,"country":55,"cosmosGeoPoint":329,"geoPoint":333,"contacts":29},"Urology Austin","Austin","Texas","78759",{"type":57,"coordinates":330},[331,332],-97.74306,30.26715,{"lat":332,"lon":331},{"facility":335,"status":51,"city":336,"state":327,"zip":337,"country":55,"cosmosGeoPoint":338,"geoPoint":342,"contacts":29},"Urology Clinics of North Texas","Dallas","75231",{"type":57,"coordinates":339},[340,341],-96.80667,32.78306,{"lat":341,"lon":340},{"facility":344,"status":51,"city":345,"state":327,"zip":346,"country":55,"cosmosGeoPoint":347,"geoPoint":351,"contacts":29},"Baylor College of Medicine","Houston","77030",{"type":57,"coordinates":348},[349,350],-95.36327,29.76328,{"lat":350,"lon":349},{"facility":353,"status":51,"city":354,"state":327,"zip":355,"country":55,"cosmosGeoPoint":356,"geoPoint":360,"contacts":29},"Urology San Antonio","San Antonio","78229",{"type":57,"coordinates":357},[358,359],-98.49363,29.42412,{"lat":359,"lon":358},{"facility":362,"status":51,"city":363,"state":364,"zip":365,"country":366,"cosmosGeoPoint":367,"geoPoint":371,"contacts":29},"Epworth Freemasons-Victoria Parade","Richmond","Victoria","3121","Australia",{"type":57,"coordinates":368},[369,370],145.00176,-37.81819,{"lat":370,"lon":369},{"facility":373,"status":51,"city":374,"state":375,"zip":29,"country":375,"cosmosGeoPoint":376,"geoPoint":380,"contacts":29},"Istituti Fisioterapici Ospitalieri (IFO)","Rome","Italy",{"type":57,"coordinates":377},[378,379],12.51133,41.89193,{"lat":379,"lon":378},{"facility":382,"status":51,"city":383,"state":29,"zip":384,"country":375,"cosmosGeoPoint":385,"geoPoint":389,"contacts":29},"Istituto Europeo di Oncologia","Milan","20141",{"type":57,"coordinates":386},[387,388],9.18951,45.46427,{"lat":388,"lon":387},{"facility":391,"status":51,"city":392,"state":29,"zip":393,"country":375,"cosmosGeoPoint":394,"geoPoint":398,"contacts":29},"Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara","Pisa","56126",{"type":57,"coordinates":395},[396,397],10.4036,43.70853,{"lat":397,"lon":396},{"facility":400,"status":51,"city":401,"state":29,"zip":402,"country":375,"cosmosGeoPoint":403,"geoPoint":407,"contacts":29},"ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie","Pozzuoli","80078",{"type":57,"coordinates":404},[405,406],14.0952,40.84394,{"lat":406,"lon":405},{"facility":409,"status":51,"city":410,"state":411,"zip":412,"country":411,"cosmosGeoPoint":413,"geoPoint":417,"contacts":29},"Centro Médico Teknon","Barcelona","Spain","08003",{"type":57,"coordinates":414},[415,416],2.15899,41.38879,{"lat":416,"lon":415},{"facility":419,"status":420,"city":421,"state":411,"zip":422,"country":411,"cosmosGeoPoint":423,"geoPoint":427,"contacts":29},"Hospital Clínico San Carlos","ACTIVE_NOT_RECRUITING","Madrid","28040",{"type":57,"coordinates":424},[425,426],-3.70256,40.4165,{"lat":426,"lon":425},{"facility":429,"status":51,"city":421,"state":411,"zip":430,"country":411,"cosmosGeoPoint":431,"geoPoint":433,"contacts":29},"Hospital Universitario 12 de Oc","28041",{"type":57,"coordinates":432},[425,426],{"lat":426,"lon":425},{"facility":435,"status":51,"city":410,"state":29,"zip":436,"country":411,"cosmosGeoPoint":437,"geoPoint":439,"contacts":29},"Hospital Quirón Barcelona","08908",{"type":57,"coordinates":438},[415,416],{"lat":416,"lon":415},{"facility":441,"status":51,"city":421,"state":29,"zip":442,"country":411,"cosmosGeoPoint":443,"geoPoint":445,"contacts":29},"MD Anderson Cancer Center - Madrid","28003",{"type":57,"coordinates":444},[425,426],{"lat":426,"lon":425},{"facility":447,"status":51,"city":421,"state":29,"zip":448,"country":411,"cosmosGeoPoint":449,"geoPoint":451,"contacts":29},"Hospital Universitario Ramón y Cajal","28034",{"type":57,"coordinates":450},[425,426],{"lat":426,"lon":425},{"facility":453,"status":51,"city":454,"state":29,"zip":455,"country":411,"cosmosGeoPoint":456,"geoPoint":460,"contacts":29},"Hospital Universitario Marqués de Valdecilla","Santander","39008",{"type":57,"coordinates":457},[458,459],-3.80493,43.46589,{"lat":459,"lon":458},{"type":462,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100592611",false,"NCT06995677","Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)","SURF302","Inclusion Criteria:\n\n* Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures\n* Able to understand and given written informed consent\n* Participants with histologically confirmed low-grade NMIBC within 6 weeks prior to randomization with prior diagnostic biopsy\u002FTURBT to confirm stage and grade and with at least 3 mm and no more than 12 mm total (1\u002F2 a resectoscope loop to 2 loops, refer to Section 8.1.5) residual visible tumor as a marker lesion(s) left behind:\n\n  1. Ta low grade\n  2. T1 low grade\n* Participants must have intermediate risk NMIBC, defined as having any of the following characteristics (AUA Guidelines, 2024)\n\n  1. Recurrence within 1 year, LG Ta\n  2. Solitary LG Ta \\>3cm\n  3. LG Ta, multifocal\n  4. LG T1\n* Documented activating FGFR3 mutation or fusion (Appendix 4)\n* Have undergone bladder mapping and identification of visible marker lesion(s) within 6 weeks prior to randomization (refer to Inclusion Criterion #3)\n* No evidence of urothelial carcinoma of the upper urinary tract (confirmed by imaging) or prostatic urethra within 6 months of randomization\n* No prior BCG administration within 1 year of date of consent.\n* No intravesical chemotherapy within 8 weeks prior to C1D1.\n* ECOG 0-1\n* Pathology consistent with pure urothelial carcinoma; if mixed histology, ensure that at least 80% of the sample is urothelial\n* Adequate bone marrow, liver, and renal function:\n\n  b. Bone marrow function: i. Absolute neutrophil count (ANC) \\> or = 1,500\u002Fmm3 ii. Platelet count \\> or = 75,000\u002Fmm3 iii. \u002Fhemoglobin \\> or = 10.0 g\u002FdL e. Liver function: i.Total bilirubin \\\u003C or = ULN ii. Alanine aminotransferase (ALT) \\\u003C or = ULN iii. Aspartate aminotransferase (AST) \\\u003C or = ULN f. Renal function: i. estimated glomerular filtration rate \\>60 mL\u002Fmin calculated using the modification of diet in renal disease equation or CKD-EPI formula ii. Serum Phosphate level \\\u003C or = ULN prior to starting treatment g. Coagulation i. International normalized ratio (INR) \\\u003C or = 1.5 x ULN\n* Ability to swallow tablets\n* Participants (male and female) of child-bearing potential (including females who are post-menopausal for less than 1 year) must be willing to practice effective contraception while on treatment and be willing and able to continue contraception for 3 months (males) and 6 months (females) after the last dose of study treatment. Potential male participants should consider the potential impact of TYRA-300 on their ability to father a child and discuss options with the site study staff.\n* Potential participants who are positive for human immunodeficiency virus (HIV) must have a viral load below the limits of detection and on stable antiretroviral therapy for at least 3 months prior to C1D1. NOTE: some of the compounds in antiretroviral therapy may be on the prohibited medications list. Allowances will be made to ensure the participant's HIV treatment continues uninterrupted following a discussion with the Sponsor's medical monitor. A discussion of the impact of the antiretroviral therapy on TYRA- 300 needs to be discussed with the potential participant prior to C1D1.\n* Potential participants with chronic hepatitis B virus (HBV) infection with active disease should be on a suppressive antiviral therapy prior to C1D1.\n* Potential participants patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and must have a HCV viral load below the limit of quantification.\n* Potential participants with a history of HCV infection and on current treatment must have a HCV viral load below the limit of quantification\n\nExclusion Criteria:\n\n* Presence of tumor in ureter or prostatic urethra:\n* Current or previous history of muscle invasive bladder cancer\n* Current or previous history of lymph node positive and\u002For metastatic bladder cancer\n* Evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder\n* Currently receiving systemic cancer therapy (cytotoxic, immunotherapy, targeted)\n* Currently receiving treatment with a prohibited therapy (refer to Section 6.7.1)\n* Current or prior history of pelvic external beam radiotherapy\n* Current or history of receiving a prior FGFR inhibitor\n* Systemic immunotherapy within 6 months prior to randomization\n* Treatment with an investigational agent within 30 days or 5 half-lives from randomization, whichever is shorter; compounds with an unknown half-life will default to the 30 days.\n* Prior treatment with an intravesical agent within 8 weeks prior to C1D1\n* Current ongoing toxicity from previous therapy\n* Had major surgery within 4 weeks prior to C1D1\n* Any reason that in the view of the investigator, would substantially impair the ability of the participant to comply with study procedures and\u002For risk to the participant (i.e., uncontrolled diabetes)\n* Females who are pregnant, breastfeeding or planning to become pregnant within 6 months after the last dose of TYRA-300 and males who plan to father a child while enrolled in this study or within 3 months after the last dose of TYRA-300\n* Has impaired wound healing capacity\n* Serum phosphate levels above the upper limit of normal during screening\n* Any ocular condition likely to increase the risk of eye toxicity\n* Current evidence of central serous retinopathy or retinal pigmented epithelial detachment of any grade at time of baseline examination.\n* History of or current uncontrolled cardiovascular disease\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300\n* Known history of HIV infection, or active hepatitis B or C\n* History of a second primary malignancy within 3 years of signing ICF, except for nonmelanoma skin cancer and cured and active surveillance malignancies (i.e., prostate, breast) .\n* Known allergy to TYRA-300 or any excipients of the formulated product\n* Participants taking strong inhibitors and\u002For inducers of CYP3A4 enzyme\n* History of prolonged QT syndrome or baseline heart rate-corrected QT interval using Fridericia formula (QTcF) interval \\>470 ms","ALL","18 Years",{"count":473,"type":474},90,"ESTIMATED","INTERVENTIONAL",[477],"PHASE2","Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC",[480,481,482,483,484,485],"Low-grade NMIBC","FGFR Gene Amplification","FGFR Gene Alterations","FGFR3 Gene Alteration","FGFR3 Gene Mutation","FGFR3 Gene Fusions",[487,488,489,490,491],"FGFR3 gene alterations","FGFR3 gene mutations","FGFR3 gene fusions","FGFR3","Non-Muscle Invasive Bladder Cancer","2026-06-26",{"date":494,"type":495},"2026-06-29","ACTUAL",{"date":497,"type":495},"2025-06-27",{"date":499,"type":474},"2028-09",{"name":5,"class":6},45]